
AxoGen (AXGN) Stock Forecast & Price Target
AxoGen (AXGN) Analyst Ratings
Bulls say
Axogen is well-positioned for profitable and sustainable growth, with strong cash position and positive cash flow expected in fiscal year 2026. The company has a diverse product portfolio with Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. With a record topline beat in 1Q26 and broad-based revenue growth, we expect positive sales performance, with expectations of at least 20% growth and a 74-76% gross profit margin for fiscal year 2026. Additionally, new sales hires in 2025 and favorable coverage decisions from major insurers signal continued growth potential for the company.
Bears say
Axogen is facing risks such as potential competition, regulatory concerns, and technological obsolescence which may lead to lower-than-projected sales growth and an inability to achieve sustainable profitability. Additionally, the company may struggle to acquire new customers and penetrate new markets due to incomplete care guidelines in its most mature commercial market. Despite delivering double-digit year-over-year growth, Axogen's potential dilution risk and a comparable EV/Revenue multiple of 9.0x could result in a price objective of approximately $50 per share with approximately 53.2 million shares outstanding as of April 24, 2026 in its $2.9 billion total addressable market (TAM) of extremities.
This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.
AxoGen (AXGN) Analyst Forecast & Price Prediction
Start investing in AxoGen (AXGN)
Order type
Buy in
Order amount
Est. shares
0 shares